Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has shared an announcement.
Recordati S.p.A. has announced a program to purchase up to 2,000,000 of its own shares to support stock option and performance share plans for its management. The program, managed by UBS Europe SE, will run until November 7, 2025, with a maximum countervalue of €125 million, aiming to enhance management incentives and potentially impact the company’s market positioning.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati is an international pharmaceutical group listed on the Italian Stock Exchange, with origins in a family pharmacy in Northern Italy in the 1920s. The company provides therapeutic options in specialty drugs, general medicine, and rare diseases, integrating activities from clinical development to marketing across 150 countries in the EMEA, Americas, and APAC regions, employing over 4,450 people.
YTD Price Performance: -2.73%
Average Trading Volume: 25,406
Technical Sentiment Signal: Hold
Current Market Cap: €10.12B
For detailed information about REC stock, go to TipRanks’ Stock Analysis page.